Pharmaceuticals
-
How Cardiol Therapeutics Could Help Save the Most Vulnerable from Dying of COVID-19
-
This Company Is Maximizing its Growth in an Emerging Sector With a Three-Pillar Strategy
-
Open Orphan rises as Venn wins major contract renewal with biopharma play
-
A new approach to R&D could mean market domination for exciting Californian company Juva Life
-
Watershed moment for pioneering Juva Life as licensed cultivation kicks off
-
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
-
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
-
Open Orphan has a great start to 2021 with key 12-month contract renewal
-
Open Orphan wins vaccine contract extension and announces toxicology study completion
-
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
-
Numinus Wellness: A rising star in the Psychedelic Investing space!
-
Open Orphan continues to convert deal pipeline with key Venn contracts
-
Open Orphan strengthens board with Elaine Sullivan hire
-
The second-gen Covid-19 stocks offering explosive opportunities: 4D Pharma
4D Pharma (LSE:DDDD) shares have surged from an all-time low of 23.5p in March to hit as high as 122p in recent days. That’s a share price not seen...
-
Open Orphan lands another £2.5m flu challenge study contract
-
Harborside Inc: An adjusted EBITDA-positive ‘farm to shelf’ takeover target targeting $100 MILLION revenue in 2021